Praharshinie Rupasinghe

Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial

Lorenzo Guglielmetti, Elisa Ardizzoni, Marc Atger et al. · Trials · 2021 · 29 citations · Full text

Balancing access to BPaLM regimens and risk of resistance

Annelies Van Rie, Bouke C. de Jong, Praharshinie Rupasinghe et al. · The Lancet Infectious Diseases · 2022 · 28 citations · Full text

Engineering, Financial Risk Management, Risk Management +6

Refined understanding of the impact of the <i>Mycobacterium tuberculosis</i> complex diversity on the intrinsic susceptibility to pretomanid

Praharshinie Rupasinghe, Rabab Reenaers, Jens Vereecken et al. · Microbiology Spectrum · 2024 · 15 citations · Full text

Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial

Lorenzo Guglielmetti, Uzma Khan, Gustavo E. Velásquez et al. · The Lancet Respiratory Medicine · 2025 · 12 citations · Full text

Evaluating newly approved drugs in combination regimens for multidrug-resistant tuberculosis with fluoroquinolone resistance (endTB-Q): study protocol for a multi-country randomized controlled trial

Shrikant Patil, Meseret Tamirat, K S Khazhidinov et al. · Trials · 2023 · 11 citations · Full text